Repurposing the Bis-Biguanide Alexidine in Combination with Tyrosine Kinase Inhibitors to Eliminate Leukemic Stem/Progenitor Cells in Chronic Myeloid Leukemia.
Fabien MuselliLucas MourguesNathalie RochetMarielle NeboutAgnès GuerciEls VerhoeyenAdrien KrugLaurence LegrosJean-François PeyronDidier MaryPublished in: Cancers (2023)
Collectively, our results validate the use of ALX bis-biguanide to potentiate the action of conventional TKI treatment as a potential new therapeutic solution to eradicate CML LSCs.